New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Improvements in Cognitive Performance and Brain Chemistry with Cognizin(TM) Citicoline

McLean Hospital and Harvard Medical School researcher will discuss clinical study at SupplySide West in Las Vegas.

(New York, NY) October 30, 2007 – A study by Deborah Yurgelun-Todd, Ph.D. applying two complementary imaging methods, magnetic resonance spectroscopy (MRS) and functional magnetic resonance imaging (fMRI), to document the effects of Cognizin™ Citicoline on the human brain in healthy volunteers were recently completed at McLean Hospital, an affiliate of Harvard Medical School. Dr. Yurgelun-Todd will give an overview of her findings at SupplySide West as part of the Kyowa Hakko USA sponsored VendorWorks, Thursday, November 8, 10 -10:50 a.m. in the Murano Room at the Sands Convention Center.

Dr. Yurgelun-Todd, director of the Cognitive Neuroimaging and Neuropsychology Laboratories at the McLean Hospital Brain Imaging Center and associate professor of Psychiatry at Harvard Medical School, found the study indicated that after six weeks of Cognizin™ use, energy stores within the brain were increased. The clinical study using neuroimaging data also showed increased concentration, focus and improved accuracy, better performance and improved speed on cognitive tasks.

Dr. Yurgelun-Todd is an innovative leader in applying neurophysiological and cognitive methods to evaluate neurobiological changes associated with brain maturation, pharmacotherapy, neuropsychiatric disorders and substance abuse. Her research focus is on identifying the neuropsychological and neurobiological bases of risk factors for major psychiatric disorders including schizophrenia and bipolar disorder.

Cognizin™ Citicoline is the premier branded ingredient manufactured by Kyowa Hakko USA, one of the world leaders in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. The company has developed a proprietary fermentation production technique for the exclusive development of Cognizin™.

Citicoline has been used extensively for the promotion of optimal neural and cognitive function. Citicoline (Cytidine 5’- diphosphocholine also known as CDP Choline) is involved in the synthesis of phospholipids, which make up the membranes of cells, especially the pathway involving phosphatidylcholine. When taken orally, Citicoline is metabolized to yield the free nucleotide uridine and choline. Peak plasma levels occur several hours after consumption for delivery to various parts of the body. Both elements cross the blood-brain barrier, become incorporated into brain membrane phospholipids and increase the production of neurotransmitters in the central nervous system, including the synthesis of acetylcholine, noradrenaline and dopamine.

Kyowa Hakko will feature Cognizin™ at SupplySide West booth # 22033. For more information about Cognizin™ visit or email [email protected].

# # # #

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.